← Structure Therapeutics Inc.

Annual Trend FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations — ($51.3m) ($89.6m) ($122.5m) ($141.2m) ($214.8m)
Net loss — ($51.3m) ($89.6m) ($122.5m) ($141.2m) —
Depreciation — $277k $295k $992k $1.3m $1.9m
Amortization Of Securities — ($905k) ($6.0m) ($18.5m) ($15.6m) ($12.7m)
Share-based Payment Arrangement, Noncash Expense — $2.5m $8.2m $18.8m $29.0m $39.8m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — $618k —
Share-based Payment Arrangement, Expense — $2.5m $8.2m $18.8m $29.0m $39.8m
Share-based compensation expense — $2.5m $8.2m $18.8m $29.0m $39.8m
Changes in operating assets and liabilities:
Change In Working Capital — $3.0m $7.0m $3.0m ($88.0m) ($27.2m)
Change In Receivables — — $0 $0 ($100.0m) $0
Increase (Decrease) in Accounts Payable — $2.2m ($860k) $3.3m $4.8m $2.1m
Offering costs included in accounts payable and accrued expenses and other current liabilities — — $53k $100k $442k —
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities — — $48k — $894k ($4.2m)
Change In Payables And Accrued Expense — $3.7m $11.3m $11.0m $26.3m $2.1m
Accrued expenses and other current liabilities — $1.5m $12.2m $7.7m $21.5m —
Change In Accrued Expense — $1.5m $12.2m $7.7m $21.5m $24.3m
Prepaid expenses and other current assets — ($305k) ($4.0m) ($1.4m) ($16.4m) —
Change In Other Current Assets — ($60k) $15k ($5.1m) $4.4m ($34.8m)
Change In Other Current Liabilities — ($361k) ($315k) ($1.6m) ($2.3m) ($2.3m)
Net Cash Provided by (Used in) Operating Activities — ($46.1m)
($79.5m) -72.35%
($116.6m) -46.73%
($222.2m) -90.51%
($220.3m) +0.86%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment — $155k $2.2m $1.3m $3.6m ($4.2m)
Purchases of short-term investments — ($123.5m) ($417.4m) ($702.5m) ($547.4m) —
Proceeds from maturities of short-term investments — $61.5m $151.2m $344.9m $630.5m —
Cash, Cash Equivalents, and Short-term Investments — — $467.3m $883.5m $1.4b —
Net Cash Provided by (Used in) Investing Activities — ($62.1m) ($268.3m) ($358.9m) $89.8m ($415.6m)
Cash flows from financing activities:
Issuance Of Capital Stock — $31.5m $472.3m $514.6m $665.7m $0
Proceeds from Issuance of Common Stock — — — $514.6m — $0
Common Stock Issuance — $0 $472.3m $514.6m $665.7m $0
Net Other Financing Charges — ($2.5m) ($21.6m) ($1.8m) ($2.6m) ($5.1m)
Net Cash Provided by (Used in) Financing Activities — $29.0m
$451.5m +1456.25%
$515.3m +14.11%
$762.5m +47.99%
$761.5m -0.13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — ($79.2m) $103.7m $39.7m $630.1m $272.6m
Beginning Cash Position — $105.3m $26.1m $129.8m $169.5m $147.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $26.1m $129.8m $169.5m $799.6m $272.6m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Income Tax Expense (Benefit) — $17k $236k $310k $515k —
Operating lease liabilities — ($361k) ($315k) ($1.6m) ($2.3m) —
Operating lease right-of-use assets obtained in exchange for new lease liabilities — — $5.5m — $4.9m —
Additional Financial Items
Proceeds from Stock Options Exercised — $33k $800k $1.9m $4.5m —
Asset Retirement Obligation, Accretion Expense — — $21k $4k $345k —
General and Administrative Expense — $16.4m $32.7m $49.4m $61.6m —
Operating Expenses — $52.6m $102.8m $158.2m $176.6m —
Accretion of asset retirement obligation — — $21k $4k $345k —
Non-cash lease expense — $347k $634k $1.6m $2.2m —
Accretion of net investment discounts — ($905k) ($6.0m) ($18.5m) ($15.6m) —
Other non-current assets — ($60k) $15k ($5.1m) $4.4m —
Proceeds from issuance of ordinary shares — — — $514.6m $665.7m —
Payments of offering costs — — ($21.6m) ($1.8m) ($2.0m) —
Proceeds from issuance of ordinary shares under employee share purchase plan — — — $632k $921k —
Proceeds from exercise of share options — $33k $800k $1.9m $4.5m —
Beginning of the period — $26.1m $129.8m $169.5m $799.6m —
Cash Flow From Continuing Financing Activities — $29.0m $451.5m $515.3m $762.5m $761.5m
Cash Flow From Continuing Investing Activities — ($62.1m) ($268.3m) ($358.9m) $89.8m ($415.6m)
Change In Account Payable — $2.2m ($860k) $3.3m $4.8m $2.1m
Change In Payable — $2.2m ($860k) $3.3m $4.8m $2.1m
Change In Prepaid Assets — ($305k) ($4.0m) ($1.4m) ($16.4m) ($16.6m)
Changes In Cash — ($79.2m) $103.7m $39.7m $630.1m $125.6m
End Cash Position — $26.1m $129.8m $169.5m $799.6m $272.6m
Financing Cash Flow — $29.0m
$451.5m +1456.25%
$515.3m +14.11%
$762.5m +47.99%
$761.5m -0.13%
Free Cash Flow — ($46.3m) ($81.7m) ($117.9m) ($225.8m) ($224.5m)
Gain Loss On Investment Securities $27 — — — ($10.2m) ($423)
Investing Cash Flow — ($62.1m) ($268.3m) ($358.9m) $89.8m ($415.6m)
Net PPE Purchase And Sale — ($155k) ($2.2m) ($1.3m) ($3.6m) ($4.2m)
Net Preferred Stock Issuance $103.4m $31.5m $0 — — $32k
Operating Gains Losses $27 — — — ($10.2m) ($423)
Other Non Cash Items — $347k $655k $1.6m $2.6m —
Proceeds From Stock Option Exercised — $33k $800k $2.5m $99.4m $100.9m
Purchase Of PPE — ($155k) ($2.2m) ($1.3m) ($3.6m) ($4.2m)
Stock Based Compensation — $2.5m $8.2m $18.8m $29.0m $39.8m
Net Investment Purchase And Sale — ($62.0m) ($266.2m) ($357.6m) $93.4m ($411.4m)
Purchase Of Investment — ($123.5m) ($417.4m) ($702.5m) ($547.4m) ($1.0b)
Sale Of Investment — $61.5m $151.2m $344.9m $640.8m $623.1m
Net change in cash and cash equivalents — ($79.2m) $103.7m $39.7m $630.1m —
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — ($79.2m) $103.7m $39.7m $630.1m —
Income Taxes Paid, Net — — — — $634k —

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.